Sign In
Last checked at 
19 Jun 2026 07:00
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Trellus Health plc
("Trellus Health", "Company" or "Group")
$260,000 Loan and Related Party Transaction
Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, announces that the Company's wholly-owned subsidiary, Trellus Health Inc., has entered into a $260,000 loan agreement ("Loan") with Mount Sinai Health System. The Loan extends the Group's cash runway until 31 July 2026.
As previously announced, the Board has engaged corporate restructuring advisors and continues its conversations with relevant parties around strategic options and opportunities for further funding, with such options including a possible sale of Trellus Health Inc., the Company's US subsidiary. There can be no certainty that any further funding will be forthcoming or transaction concluded nor as to terms thereon. The Board also continues to take action to protect wider stakeholders' interests.
Interest on the Loan, which is unsecured, will accrue at an annual rate of 8% with effect from 19 December 2026, payable on maturity of the Loan. The Loan falls due for repayment at the earlier of (i) 19 June 2027; or (ii) 90 days following the close of a sale of Trellus Health Inc.
The Company's ordinary shares remain suspended from trading on AIM effective 08 May 2026 pending clarification of the Company's financial position. Further announcements will be made as appropriate.
Related Party Transaction
The Loan by Mount Sinai Health System is deemed to be a related party transaction under AIM Rule 13 of the AIM Rules for Companies. The Company's Directors (excluding those who are connected to Mount Sinai) consider, having consulted with the Nominated Adviser, Singer Capital Markets, that the terms of the related party transaction are fair and reasonable insofar as the shareholders of the Company are concerned.
Enquiries:
Trellus Health plc | https://trellushealth.com/
| ||||
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder | Via Walbrook PR | ||||
Joy Bessenger, Chief Financial Officer | |||||
Singer Capital Markets (Nominated Adviser and Broker) | |||||
Peter Steel / Jalini Kalaravy / Samed Ethemi | Tel: +44 (0)20 7496 3000 303 | ||||
Walbrook PR | Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com | ||||
Lianne Applegarth / | Mob: +44 (0)7584 391 303/ | ||||
Alice Woodings
| +44 (0)7407 804 654
| ||||
About Trellus Health plc (www.trellushealth.com)
Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com
Follow the stocks
